LP
DFTX

LMR Partners’s Definium Therapeutics DFTX Stock Holding History

LMR Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.07M Buy
+150,200
New +$3.71M 0.03% 539
2024
Q2 		– Sell
-16,374
Closed -$154K – 1230
2024
Q1 		$154K Buy
+16,374
New +$93.4K ﹤0.01% 893
2022
Q4 		– Sell
-10,211
Closed -$36K – 1206
2022
Q3 		$36K Buy
+10,211
New +$98K ﹤0.01% 1126

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LMR Partners's DFTX Position: Q2 2026 in Review

LMR Partners opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 150,200 shares worth $7.07M. The stake represents 0.03% of the portfolio and ranks #539 among its holdings. This is a return to the name: LMR Partners previously reported a position in DFTX as recently as Q1 2024.

LMR Partners first reported a position in DFTX in Q3 2022 and has held it in 3 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • LMR Partners held 150,200 shares of Definium Therapeutics worth $7.07M as of Q2 2026.
  • Definium Therapeutics was a new LMR Partners position in Q2 2026.
  • Definium Therapeutics made up 0.03% of LMR Partners's portfolio in Q2 2026, its #539 holding.
  • LMR Partners first reported a position in Definium Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.